Drug-induced liver injury in obesity  by Fromenty, Bernard
Hepatology SnapshotDrug-induced liver injury in obesity
Bernard Fromenty⇑
INSERM, UMR991, Université de Rennes 1, Rennes, FranceMany countries are facing an epidemic of obesity that can be
explained, at least in part, by a sedentary life style and calorie
overconsumption. This poses a major issue for public health since
obesity primarily enhances the risk of various illnesses such as
type 2 diabetes, coronary heart disease, some cancers and non-
alcoholic fatty liver disease (NAFLD). Consequently, obese
patients are consuming on average more drugs than non-obese
individuals [1]. This could pose another medical issue, in partic-
ular for hepatologists, since many drugs are able to induce liver
injury [2,3]. Moreover, there is growing evidence that obesity
and NAFLD can increase the risk of drug-induced liver injury
(DILI), at least for some drugs [3,4]. Thus, obese patients could
be more prone to develop DILI as a consequence of drug overcon-
sumption and an intrinsic susceptibility of their diseased liver to
drug-induced hepatotoxicity.
Actually, DILI in obese patients could occur as two distinct clin-
ical settings. Indeed, in the context of obesity and relatedmetabolic
diseases, some drugs seem to aggravate pre-existing NAFLD
whereas others could induce more frequently an acute hepatitis
(Fig. 1). Drugs that could aggravate NAFLD in obese patients are
tamoxifen, irinotecan,methotrexate and nucleoside reverse trans-
criptase inhibitors (NRTIs) such as stavudine and didanosine
(Table 1 in Fig. 1) [3,5–7]. Aggravation of NAFLD has also been doc-
umented in different animal models with rosiglitazone, tetracy-
cline, phenobarbital and pentoxifylline (Table 1 in Fig. 1) [3,8].
Drugs that could induce acute liver injurymore often in obese indi-
viduals are the volatile halogenated anesthetic halothane and iso-
ﬂurane, acetaminophen (APAP), and other drugs such as losartan,
ticlopidine and omeprazole (Table 1 in Fig. 1) [3,9–11]. However,
it is noteworthy that the list of drugs in Table 1 is temporary and
should expand in the future asDILI in the context of obesity is gain-
ing growing attention. In this ‘‘Snapshot’’ article, I will put forward
several potentialmechanismswhereby drugs can bemore hepato-
toxic in obese individuals. Since these mechanisms have mostly
been discovered during experimental studies, any extrapolation
to humans should be done with caution.
Drug-induced worsening of NAFLD could be explained by dif-
ferent mechanisms (Fig. 1B). Regarding fatty liver, some drugs
could be able to stimulate lipogenesis in steatotic liver, but notJournal of Hepatology 20
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Open access under CC BY-NC-ND license.in normal liver, by activating lipogenic transcription factors such
as peroxisome proliferator-activated receptor-c (PPARc) (e.g. ros-
iglitazone), pregnane X receptor (e.g. tamoxifen) and carbohy-
drate response element-binding protein (e.g. pentoxifylline)
[3,8]. Because numerous drugs are able to alter mitochondrial
function [2,3], it is conceivable that impaired mitochondrial fatty
acid oxidation (mtFAO) could also be involved in drug-induced
aggravation of fatty liver. Importantly, increased FAO during
NAFLD is a key adaptive mechanism in order to restrain fat accre-
tion [12,13], and thus any impediment to this adaptation could
signiﬁcantly aggravate fatty liver (Fig. 1B). Reduced VLDL secre-
tion could be involved, as several drugs were shown to interfere
with VLDL synthesis by inhibiting microsomal triglyceride trans-
fer protein (MTP) activity (e.g. amiodarone, tianeptine) [14] or
apolipoprotein B-100 synthesis (e.g. mipomersen) [15] (Fig. 1B).
Some drugs are also able to induce oxidative stress [3,16], which
can trigger the progression of simple steatosis to non-alcoholic
steatohepatitis (NASH) (Fig. 1B). Drug-induced oxidative stress
could have several origins, in particular through glutathione
(GSH) depletion and inhibition of the mitochondrial respiratory
chain (MRC) [3,16]. The pre-existent reduction of GSH levels
and MRC activity in NAFLD [12] could prime drug-induced oxida-
tive stress and accelerate the progression of fatty liver to NASH.
Unlike ethanol overconsumption, which is known to aggravate
NAFLD [4,17], it is still unknown whether drugs able to aggravate
NAFLD can stimulate the production of proinﬂammatory and ﬁbr-
ogenic cytokines such as TNFa and TGFb, respectively.
It is worth mentioning that drug-induced aggravation of
NAFLD can also be secondary to the worsening of insulin resis-
tance (IR), a key mechanism leading to hepatic lipid deposition
(Fig. 1A). Indeed, worsening of IR exacerbates not only hepatic
lipogenesis secondary to hyperinsulinemia but also the delivery
of free fatty acids (FFA) to the liver due to adipose triacylglycerol
hydrolysis. Drugs known to trigger (or worsen) IR are, for
instance, synthetic corticosteroids, antipsychotic drugs (e.g. clo-
zapine, olanzapine), NRTIs, protease inhibitors and thiazide
diuretics (e.g. hydrochlorothiazide) [3,5–7,18].
Higher risk of drug-induced acute hepatitis in obesity could be
related to increased activity of several cytochromes P450 (CYPs),
which could enhance the generation of toxic metabolites
(Fig. 1C). Indeed, increased activity of several CYPs such as
CYP1A2, CYP2C9, CYP2D6 and CYP2E1 has been documented in
obese individuals [4,19]. Higher CYP2E1 activity could explain
why drugs such as halothane and APAP seem to be more hepato-
toxic in the context of obesity and NAFLD since CYP2E1 trans-
forms these drugs into the highly reactive metabolites
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Aggravation 
of pre-existing NAFLD
Drugs Therapeutic class
Corticosteroids Anti-inflammatory
Irinotecan Anticancer
Methotrexate Immunosuppressant, antimetabolite
NRTIs (e.g., stavudine, didanosine) Antiretroviral 
Pentoxifylline Hemorrheologic agent, anti-TNFα
Phenobarbital Antiepileptic 
Protease inhibitors (e.g., ritonavir) Antiretroviral
Rosiglitazone Antidiabetic (PPARγ agonist)
Tamoxifen Anticancer
Tetracycline Antibiotic
Acute hepatitis 
in obesity and NAFLD
Table 1.  Drugs shown - or suspected- to aggravate pre-existing NAFLD, 
or to induce more frequently an acute hepatitis in the context of obesity and NAFLD,
according to clinical (in italics) and experimental investigations
Drugs Therapeutic class
Acetaminophen (APAP) Analgesic 
Fosinopril Antihypertensive
Halothane Volatile anesthetic
Haloperidol Antipsychotic
Isoflurane Volatile anesthetic
Losartan Antihypertensive 
Omeprazole Proton pump inhibitor
Piperacillin-Tazobactam Antibiotic
Telithromycin Antibiotic
Ticlopidin Inhibitor of platelet aggregation
A
B
C
Fig. 1. Schematic pathophysiology of obesity-associated non-alcoholic fatty liver disease (NAFLD) and mechanisms whereby some drugs can induce, or aggravate,
liver injury in the context of NAFLD.
JOURNAL OF HEPATOLOGY(NAPQI), respectively [4,20]. When generated in excess, these
reactive metabolites can induce hepatic oxidative stress, severe
mitochondrial dysfunction and cytolysis (Fig. 1C) [4,20]. It is
noteworthy that higher risk of APAP-induced acute liver injury
in obese individuals with NAFLD is mostly suspected in the con-
text of APAP overdose [10,21], although therapeutic doses of this
pain killer could also be involved [22]. Another mechanism that
could explain higher risk of drug-induced acute hepatitis in obes-
ity is reduced levels of GSH, in particular at the mitochondrial
level [12], which could impair the removal of CYP-generated
reactive metabolites (Fig. 1C). Because obesity is associated with
reduced activity of some CYPs such as CYP3A4 [19], higher risk of
acute hepatitis is not expected with all drugs able to generate
toxic metabolites. Moreover, enhanced glucuronosyltransferase
activity seems to be common in obesity [19,20], which may favor
the detoxication of some compounds. Finally, it is also notewor-
thy that under-dosing is expected with drugs whose dosage is not
adapted to higher body mass index. Clearly, more investigations
are needed in order to decipher the mechanisms whereby someJournal of Hepatology 201drugs are more toxic on the obese liver. From a clinical viewpoint,
a better identiﬁcation of the drugs presenting such harmful
effects is urgently warranted. This should prompt physicians to
carry out a regular monitoring of liver function in obese patients
treated with these drugs in order to detect any deterioration of
the pre-existing NAFLD, or the occurrence of acute hepatitis.Conﬂict of interest
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